| All Releases |
|---|
 |
European Patent Office Grants Patent for the Use of Vigabatrin/CPP-109 for the Prevention of Addiction to Opioids in Pain Management
07/09/10
|
14.2 KB
|
| |
CORAL GABLES, Fla., Jul 9, 2010 (GlobeNewswire via COMTEX News Network) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opio...
|
|
|
Vigabatrin/CPP-109 Data to be Presented at College on Problems of Drug Dependence Annual Meeting
06/09/10
|
11.6 KB
|
| |
CORAL GABLES, Fla., June 9, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that on Tuesday, June 15th at 5:20pm local time, Charles Gorodetzky, MD, PhD will deliver a presentation entitled "Vigabatrin for the treatment of stimulant dependence" at the College on Problems of Drug Dep...
|
|
|
Catalyst Pharmaceutical Partners Announces First Quarter 2010 Financial Results
05/18/10
|
17.2 KB
|
| |
CORAL GABLES, Fla., May 18, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced its financial results for the three month period ended March 31, 2010. The Company reported a net loss of $1,045,043, or $0.06 per basic and diluted share, compared to a net loss of $3,031,201, or $0.22 per...
|
|
|
Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference
05/07/10
|
11.2 KB
|
| |
CORAL GABLES, Fla., May 7, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that Jack Weinstein, Catalyst's Chief Financial Officer, will be making a presentation at the MoneyShow Conference to be held May 10th through May 13th at Caesars Palace in Las Vegas. Catalyst will present a Cor...
|
|
|
Catalyst Pharmaceutical Partners Regains Compliance with NASDAQ Minimum Bid Price Rule
04/26/10
|
11.3 KB
|
| |
CORAL GABLES, Fla., April 26, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it has received notice from The NASDAQ Stock Market ("NASDAQ") confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capi...
|
|
|
Catalyst Pharmaceutical Partners Signs Definitive Agreement With the National Institute on Drug Abuse To Conduct U.S. Phase II(B) Clinical Trial for Cocaine Addiction
04/13/10
|
13.3 KB
|
| |
CORAL GABLES, Fla., April 13, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formula...
|
|
|
CPP-109 Clinical Trial Data to be Presented at the American Society of Addiction Medicine Annual Medical-Scientific Conference
04/09/10
|
11.8 KB
|
| |
CORAL GABLES, Fla., April 9, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, ...
|
|
|
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2009 Financial Results
04/01/10
|
19.2 KB
|
| |
CORAL GABLES, Fla., April 1, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter a...
|
|
|
Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
03/10/10
|
11.2 KB
|
| |
CORAL GABLES, Fla., March 10, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced that Patrick J. McEnany, Catalyst's Chief Executive Officer, will be making a presentation at the BioNetwork East 2010 Conference to be held March 15th through March 17th at the Eden Roc Resort and Spa on Miami ...
|
|
|
Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
02/25/10
|
11.6 KB
|
| |
CORAL GABLES, Fla., Feb 25, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced that it will be making a presentation today at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum being held at the Hyatt Embarcadero Hotel in San Francisco. For additional program inform...
|
|
|
Catalyst Pharmaceutical Partners and The National Institute on Drug Abuse Plan to Initiate U.S. Phase II(b) Clinical Trial for Cocaine Addiction
02/23/10
|
13.1 KB
|
| |
CORAL GABLES, Fla., Feb 23, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, fo...
|
|
|
Catalyst Pharmaceutical Partners to Discuss Development Plans for CPP-115 on February 23, 2010 Conference Call
02/22/10
|
18.7 KB
|
| |
CORAL GABLES, Fla., Feb 22, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) will hold a conference call on Tuesday, February 23, 2010 to discuss its initial development plans for CPP-115. Patrick J. McEnany, Catalyst Pharmaceutical's Chief Executive Officer, will host the call.
CPP-115 is a compo...
|
|
|
Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
02/17/10
|
15.7 KB
|
| |
CORAL GABLES, Fla., Feb 17, 2010 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held Feb...
|
|
|
Catalyst Receives Guidance from Nasdaq Regarding Minimum Bid Price Requirement
11/13/09
|
12.3 KB
|
| |
CORAL GABLES, Fla., Nov 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it received a Nasdaq Staff Deficiency Letter dated November 13, 2009 indicating that the Company is not in compliance with the Minimum Bid Price requirement set forth in Nasdaq Listing Rule ...
|
|
|
Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
11/12/09
|
16.7 KB
|
| |
CORAL GABLES, Fla., Nov 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) today reported financial results for the third quarter and nine months ended September 30, 2009.
Third Quarter 2009 ResultsFor the quarter ended September 30, 2009, the Company reported a net loss of $1,286,720...
|
|
|
U.S. Department of Defense Awards $1.2 Million to Study the Use of Vigabatrin to Reduce the Addictive Liability of Opiates While Still Effectively Managing Pain
11/10/09
|
16.0 KB
|
| |
CORAL GABLES, Fla., Nov 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) today reported that a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System (LIJ) has received a $1.2 million grant from the U.S. Department of D...
|
|
|
Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executive's Employment Agreement
10/13/09
|
13.2 KB
|
| |
CORAL GABLES, Fla., Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced two organizational changes and the extension of the term of Patrick J. McEnany's employment agreement with the Company for an additional two years.
Organizational ChangesThe Company announced that...
|
|
|
Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
10/06/09
|
12.5 KB
|
| |
CORAL GABLES, Fla., Oct 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that it has closed its previously announced registered direct offering of 3.97 million shares of its common stock to institutional investors at a price per share of $1.00, representing gross procee...
|
|
|
Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
10/01/09
|
13.8 KB
|
| |
CORAL GABLES, Fla., Oct 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that it has entered into definitive agreements to sell 3.97 million shares of its common stock at a price per share of $1.00 pursuant to a registered direct offering to several select institutiona...
|
|
|
Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
09/30/09
|
18.4 KB
|
| |
CORAL GABLES, Fla., Sept 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that the Company will continue to develop CPP-109 (Catalyst's version of vigabatrin) for the treatment of cocaine and methamphetamine addiction. The Company's decision was made after, and based up...
|
|
|
